Effect of Mesenchymal Stem Cells in Primary Knee Osteoarthritis

NCT05783154 | Unknown Phase 2 DMC

• 1 other identifier: BSMMU/2022/8897
• Study Type: interventional
• Target: 84
• Locations: 1 country
• Sites: 1

Brief Summary

Osteoarthritis (OA) is the most prevalent chronic joint disorder worldwide and is associated with significant pain and disability. Incidence and prevalence of osteoarthritis rise with increasing age. The prevalence of OA knee in Bangladesh seems to be higher due to poor working conditions, heavy physical labor, and occupational injuries which increase in the future. This will ultimately create a higher clinical and socioeconomic burden on the population and national economy. The course of the disease varies but is often progressive. OA of the knee is one of the common self-reported musculoskeletal pain conditions causing patients to visit the Physical Medicine and Rehabilitation (PM\&R) department, at BSMMU. The primary objectives of knee OA treatment focus on pain reduction, and joint mobility improvement, as well as the reduction of disease progression and preserving patients' independence and quality of life. Current treatments aim at alleviating these symptoms by several different methods: Non-pharmacological treatments, Pharmacological treatments, and Invasive interventions. Mesenchymal stem cells (MSCs) therapies for knee osteoarthritis are being investigated in various corners of the world. Both positive and negative findings were observed in that research. Although, the effectiveness of MSCs in KOA is not yet well known. Some studies found MSCs effective, and safe in KOA, and it has the potential to regenerate/heal degraded joint cartilage. MSCs can differentiate into cartilage tissue. Furthermore, MSCs have been shown to have paracrine anti-inflammatory and immunomodulatory effects by producing different growth factors and cytokines. This therapeutics option is under investigation to date. The objective of this trial is to find the effectiveness, safety, and dose difference of adipose tissue-derived stem cells (AT-MSCs) therapy for the treatment of knee osteoarthritis (KOA). But in fact, there is no published data about the effectiveness of autologous adipose tissue-derived mesenchymal stem cells injection on pain, joint functioning, and femoral cartilage thickness in the management of knee osteoarthritis in Bangladesh. Henceforth, this trial will generate new knowledge about the effectiveness, safety, and appropriate dose of AT-MSCs for KOA. So this research will be helpful to generate evidence-based information for an effective treatment option for the management of KOA.

Conditions

Osteoarthritis Knee

Keywords

Osteoarthritis; Pain; Mesenchymal Stem Cell Therapy; Physical function; Outcome, Effectiveness; Disability; Quality of Life

Outcome Measures

Primary Outcomes (4)

• Changes in the Articular Cartilage Defect

  Cartilage defect will be evaluated by MRI Osteoarthritis Knee score (MOAKS). MOAKS will be considered to describe the cartilage defect. In MOAKS the knee is divided into 14 articular sub-regions for scoring articular cartilage and Bone Marrow Lesions (BML) \[0-100%\] where higher score indicates more bone-marrow-lesion and the BML grades are as follows: grade 0= none, grade 1 \<33%, grade 2= 33-66% and grade 3 \>66%.

  Cartilage defect will be measure before and after treatment at the month 6 and 12.

• Changes in Femoral Cartilage thickness

  Femoral cartilage thickness will be measured at the three level specifically medial condyle, lateral condyle and intercondylar notch using high frequency ultrasound (Machine Model: Chison Qbit-7, Transducer: 15 mega hertz (MHz) Linear). Mean value of the three measurement will be considered for mean femoral cartilage thickness (0-4 mm).

  Mean femoral cartilage will be measured before and after treatment at the month 6, and12.

• Changes in the Pain Intensity

  Pain intensity of the knee joint will be evaluated by visual analogue scale (VAS) ranges between 0 to 10 (0-10 cm scale) where score 0 indicate 'no pain' and 10 indicates 'worst pain'.

  Pain intensity will be measured before and after treatment at the month 1, 3, 6, and12

• Changes in Physical functioning

  Physical functioning will be measured by The Western Ontario and McMaster Universities Arthritis Index (WOMAC) scale. WOMAC has 17 item Physical Function measure where each item score ranges between 0 to 4, and total physical function score ranges between 0-68. The higher score indicates worse physical function of the joint examined.

  Physical functioning will be measured before and after treatment at the month 1, 3, 6, and 12

Secondary Outcomes (1)

• Any Complications arises

  At the month 1, 3, 6, and 12 after treatment as well as at anytime within 12 months of the treatment (if required)

Study Arms (2)

Control Group (Group-1)

NO INTERVENTION

In control group: 42 patients with primary KOA will receive standard conventional care including rehabilitation for knee osteoarthritis.

Experimental Group (Group-2)

EXPERIMENTAL

In the interventional group, another 42 patients with primary KOA will receive adipose tissue-derived mesenchymal stem cells (AT-MSCs) injection intra-articularly (Group-2). However, group-2 (Interventional group) will be subdivided into two sub-groups namely group-2a, and group-2b. A total of 21 Participants of group-2a will receive single doses of autologous adipose tissue-derived stem cell (AT-MSCs) and standard conservative care including rehabilitation for KOA. Whereas, group-2b, 21 respondents will receive two doses of autologous adipose tissue-derived stem cell (AT-MSCs) at 3 months intervals along with standard conservative care including rehabilitation for KOA.

Biological: Autologous Adipose Tissue-Derived Mesenchymal Stem Cell

Interventions

Autologous Adipose Tissue-Derived Mesenchymal Stem Cell BIOLOGICAL

After cleaning the knee with 10% povidone-iodine (Povidep10% solution, manufactured by Jayson Pharmaceuticals limited, Bangladesh) and draping it in a sterile manner, the injection site will be anesthetized with 0.5% bupivacaine (Inj. Bupi Heavy 0.5%, Manufactured by Popular Pharmaceuticals limited, Bangladesh) superficially outside of joint capsule. Within one hour of preparation, the autologous AT-MSC will be injected into each knee joint through medial tibio-femoral compartment in group -I using a 38-mm 18- gauge needle

Experimental Group (Group-2)

Eligibility Criteria

• Age: 40 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Primary osteoarthritis of the target knee refractory to conventional treatment only.
• Age between 40-70 years.
• All the genders.
• Participant with knee pain who fulfill 2016 revised American College of Rheumatology (ACR) criteria for OA knee
• The Kellgren and Lawrence Grade ≥2 patients.
• Pain score \>3 on Visual analog scale \[VAS\], (0-10 cm scale).

You may not qualify if:

• Previous diagnosis of poly-articular disease
• Severe mechanical extra-articular deformation (\>15° varus/15° valgus)
• Systemic auto-immune rheumatic disease
• Arthroscopy or intra-articular infiltration in the last 6 months
• Chronic treatment with Immunosuppressive or anticoagulant drugs
• Corticosteroids treatment in the 3 last months
• Non-steroidal anti-inflammatory drugs therapy in the last 15 days
• Poorly controlled Diabetes mellitus, blood dyscrasias
• Septic or tubercular arthritis
• Recent trauma, fracture, and unstable knee joint

Sponsors & Collaborators

• Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh: lead

Study Sites (1)

Bangabandhu Sheikh Mujib Medical University

Dhaka, Bangladesh

RECRUITING

MeSH Terms

Conditions

Osteoarthritis, Knee; Osteoarthritis; Pain

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Moshiur Rahman Khasru, MBBS, FCPS

  Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Moshiur Rahman Khasru, MBBS, FCPS

CONTACT

+8801716045646; drkhasrupmr@bsmmu.edu.bd

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: February 3, 2023
• First Posted: March 24, 2023
• Study Start: September 16, 2022
• Primary Completion: July 31, 2024
• Study Completion: September 30, 2024
• Last Updated: March 24, 2023

Record last verified: 2023-03

Locations

BA (1)